



Patent Application
U.S. Serial No. 09/761,995
Attorney Docket No. PC10759A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	Chen, Yuhpyng L.	:	Examiner: Truong, T. N.
APPLICATION NO.:	09/761,995	:	Group Art Unit: 1624
FILING DATE:	01/17/2001	:	
TITLE:	CORTICOTROPIN RELEASING FACTOR ANTAGONISTS	:	

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

| 07/21/2003 GGEBREGI 00000144 161445 09761995
01 FC:1814 110.00 DA

Sir:

TERMINAL DISCLAIMER

Petitioner, PFIZER INC, a corporation organized under the laws of the State of Delaware, having its principal place of business at 235 East 42nd Street, New York, NY 10017-5755, certifies that it is the assignee of record of the entire right, title and interest in and to (a) the present patent application 09/761,995, filed January 17, 2001, by virtue of an Assignment by the inventor dated May 7 2002 and filed June 20 2002, (b) U.S. Patent No. 5,962,479, and (c) U.S. serial No. 08/765,110.

Pfizer Inc hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the present application (U.S. serial no. 09/761,995), which would extend beyond the expiration date of the full and complete statutory term of the prior patent (U.S. patent 5,962,479) or of any patent issuing from the prior application (U.S. serial No. 08/765,110), wherein said full and complete statutory term is as defined in 35 U.S.C. §§154 to 156 and 173, including any term extensions thereto authorized or which may be authorized by law, and as presently shortened by any terminal disclaimer.

Pfizer hereby agrees that any patent granted on the present application shall be enforceable only for and during such period that the present application, the prior patent and any patent issuing from the prior application are commonly owned. This particular agreement

15

runs with any patent granted on the present application and is binding upon the grantee and its successors or assigns.

In making the above disclaimer, Pfizer Inc does not disclaim the terminal part of any patent granted on the present application that would extend to the expiration date of the full and complete statutory term of the prior patent or of any patent issuing from the prior application, wherein said full and complete statutory term is as defined in 35 U.S.C. §§154 to 156 and 173, including any term extensions thereto authorized or which may be authorized by law, and as presently shortened by any terminal disclaimer, in the event that the prior patent or any patent issuing from the prior application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of common jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a re-examination certificate, is reissued, or in any manner terminated prior to the expiration of its full and complete statutory term as presently shortened by any terminal disclaimer.


The Commissioner is hereby authorized to charge the appropriate fee for submission of this Terminal Disclaimer under 37 C.F.R. § 1.20(d) and any other additional fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 16-1445.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

7/14/2003

Respectfully submitted,



Andrea Dorigo
Attorney for Applicants
Reg. No. 47,532

Pfizer, Inc
Patent Department
150 East 42nd Street (150/05/49)
New York, NY 10017
(212) 733-5086